REGISTERED NUMBER: 15499226 (England and Wales)

FINANCIAL STATEMENTS

FOR THE PERIOD

18 FEBRUARY 2024 TO 28 FEBRUARY 2025

FOR

MIDLAND PHARMACEUTICALS LTD

Page

Company Information

1

Balance Sheet

2

Notes to the Financial Statements

3

DIRECTOR:

P Suzdak

REGISTERED OFFICE:

C/o Philip Lee

30th Floor Leadenhall Building

122 Leadenhall St

London

EC3V 4AB

REGISTERED NUMBER:

15499226 (England and Wales)

AUDITORS:

Armstrongs Accountancy Ltd

Chartered Accountants and Statutory Auditor

1 & 2 Mercia Village

Torwood Close

Westwood Business Park

Coventry

West Midlands

CV4 8HX

CURRENT ASSETS

Debtors

4

5,100

Cash at bank

99,852

104,952

CREDITORS

Amounts falling due within one year

5

7,439

NET CURRENT ASSETS

97,513

TOTAL ASSETS LESS CURRENT LIABILITIES

97,513

CREDITORS

Amounts falling due after more than one year

6

130,726

NET LIABILITIES

(33,213

)

CAPITAL AND RESERVES

Called up share capital

8

Retained earnings

(33,221

)

(33,213

)

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 6 November 2025 and were signed by:

P Suzdak - Director

1.	STATUTORY INFORMATION

Midland Pharmaceuticals Ltd is a private limited company, limited by shares, registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£), rounded to the nearest pound.

2.	ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Foreign currencies

Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

Going concern

The company is currently in the product development phase and intends to raise funds through series A financing by the end of 2025. The director is confident that the company has adequate support and funds to sustain its product development activities. Therefore the financial statements have been prepared on going concern basis due to the company's ability to continue its operation.

3.	EMPLOYEES AND DIRECTORS

The average number of employees during the period was NIL.

4.

DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

£

Amounts owed by group undertakings

4,013

Directors' current accounts

7

Prepayments and accrued income

1,080

5,100

5.

CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

£

Trade creditors

3,659

Accrued expenses

3,780

7,439

6.

CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR

£

Other loans - 2-5 years

130,726

7.	DISCLOSURE UNDER SECTION 444(5B) OF THE COMPANIES ACT 2006

The Report of the Auditors was unqualified.

Muhammed Shabbir (Senior Statutory Auditor)

for and on behalf of Armstrongs Accountancy Ltd

8.	ULTIMATE CONTROLLING PARTY

The ultimate controlling party is NLC Ventures Netherlands B.V..

The registered address of the parent is 25 Paasheuvelweg, Amsterdam, Netherlands 1105 BP.